Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73307
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73307
Character Range: 9973–11065

73307              A test of tumour tissue from a patient with advanced (FIGO III‑IV), high‑grade serous or other high‑grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:                                                                                                                                                                                                                                                                                                                                                                                                                      3,000.00
                     (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]‑ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and
                     (b) including a service described in item 73301

                   Applicable once per primary tumour diagnosis